[go: up one dir, main page]

MA26875A1 - Composes azapolycycliques a noyau aryle condensé - Google Patents

Composes azapolycycliques a noyau aryle condensé

Info

Publication number
MA26875A1
MA26875A1 MA26775A MA26775A MA26875A1 MA 26875 A1 MA26875 A1 MA 26875A1 MA 26775 A MA26775 A MA 26775A MA 26775 A MA26775 A MA 26775A MA 26875 A1 MA26875 A1 MA 26875A1
Authority
MA
Morocco
Prior art keywords
compounds
condensed aryl
formula
azapolycyclic
azapolycyclic compounds
Prior art date
Application number
MA26775A
Other languages
English (en)
Inventor
Wadsworth Coe Jotham
Roanne Palmer Brooks Paige
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA26875A1 publication Critical patent/MA26875A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/24—Camphidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

DEPOSANT Société dite : PFIZER PRODUCTS INC, REVENDICATION DE PRIORITES US 25 Février 2000 09/514,002 Voir en annexe le titre de l'invention et le texte de l'abrégé Composés azapolycycliques à noyau aryle condensé L'invention concerne des composés de formule I et leurs sels pharmaceutiquement acceptables, formule dans laquelle R1, R2 et R3 répondent aux définitions figurant dans le présent mémoire ; des intermédiaires pour la synthèse de ces composés, des compositions pharmaceutiques contenant ces composés ; et des méthodes d'utilisation de ces composés dans le traitement de troubles neurologiques et psychologiques.
MA26775A 2000-02-25 2002-08-13 Composes azapolycycliques a noyau aryle condensé MA26875A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/514,002 US6605610B1 (en) 1997-12-31 2000-02-25 Aryl fused azapolycyclic compounds

Publications (1)

Publication Number Publication Date
MA26875A1 true MA26875A1 (fr) 2004-12-20

Family

ID=24045406

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26775A MA26875A1 (fr) 2000-02-25 2002-08-13 Composes azapolycycliques a noyau aryle condensé

Country Status (40)

Country Link
US (3) US6605610B1 (fr)
EP (2) EP1619192B1 (fr)
JP (1) JP2003524002A (fr)
KR (1) KR100537976B1 (fr)
CN (1) CN1263745C (fr)
AP (1) AP1860A (fr)
AT (2) ATE328872T1 (fr)
AU (2) AU784081B2 (fr)
BG (1) BG65891B1 (fr)
BR (1) BR0108610A (fr)
CA (1) CA2401229C (fr)
CR (1) CR6726A (fr)
CU (1) CU23148A3 (fr)
CY (1) CY1105301T1 (fr)
CZ (1) CZ303203B6 (fr)
DE (2) DE60120366T2 (fr)
DK (2) DK1259489T3 (fr)
DZ (1) DZ3328A1 (fr)
EA (1) EA005316B1 (fr)
EE (1) EE200200475A (fr)
ES (2) ES2263640T3 (fr)
GE (1) GEP20053454B (fr)
HK (1) HK1050894A1 (fr)
HR (1) HRP20020700A2 (fr)
HU (1) HU229482B1 (fr)
IL (2) IL150639A0 (fr)
IS (1) IS2293B (fr)
MA (1) MA26875A1 (fr)
MX (1) MXPA02008311A (fr)
NO (1) NO323608B1 (fr)
NZ (1) NZ519973A (fr)
OA (1) OA12181A (fr)
PL (1) PL365163A1 (fr)
PT (1) PT1259489E (fr)
RS (1) RS51123B (fr)
SI (1) SI1259489T1 (fr)
SK (1) SK12042002A3 (fr)
UA (1) UA74813C2 (fr)
WO (1) WO2001062736A1 (fr)
ZA (1) ZA200206768B (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG102686A1 (en) * 1997-12-31 2004-03-26 Pfizer Prod Inc Aryl fused azapolycyclic compounds
DK1383733T3 (da) * 2001-04-20 2008-06-09 Pfizer Prod Inc Fremgangsmåde til fremstilling af 1,3-substituerede indener og aryl-sammenföjede azapolycykliske forbindelser
MXPA04002539A (es) * 2001-10-31 2004-05-31 Pfizer Prod Inc Combatientes de los receptores de la acetilcolina nicotinica en el tratamiento del sindrome de pierna inquietas.
WO2003045967A1 (fr) * 2001-11-30 2003-06-05 Pfizer Products Inc. Composes azapolycycliques a fusion aryle
MXPA04003807A (es) * 2001-11-30 2004-07-30 Pfizer Prod Inc Formulaciones farmaceuticas de 5, 7, 14-trianzatetraciclo [10.3.1.02, 11, 04, 9]-hexadeca -2 (11), 3, 5, 7, 9-pentaeno.
RU2326693C2 (ru) 2002-07-18 2008-06-20 Цитос Байотекнолоджи Аг Конъюгаты гаптен-носитель и их применение
WO2004037850A2 (fr) * 2002-10-22 2004-05-06 Millipore Corporation Formation par immersion de structures composites dans des plaques multi-puits et procede associe
PL377292A1 (pl) * 2002-11-25 2006-01-23 Pfizer Products Inc. Ulepszony sposób wytwarzania 1,3-podstawionych indenów
AU2004203983A1 (en) * 2003-01-15 2004-07-29 Pfizer Products Inc. Process for the preparation of aryl fused polycyclic lactams
EP1633358A1 (fr) * 2003-05-20 2006-03-15 Pfizer Products Inc. Compositions pharmaceutiques a base de varenicline
DK1638971T3 (da) * 2003-06-04 2008-10-27 Pfizer Prod Inc Fremstilling af substitueret Quinoxaliner fra dianilinen med 2,3-dihydroxy-1,4-dioxan
BRPI0412880A (pt) * 2003-07-21 2006-10-03 Pfizer Prod Inc compostos azapolicìclicos fundidos a arila
US8580842B2 (en) * 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
MXPA06004088A (es) 2003-10-14 2006-06-27 Xenoport Inc Forma cristalina de un analogo del acido gamma-aminobutirico.
BRPI0418092A (pt) * 2003-12-23 2007-04-17 Pfizer Prod Inc combinação terapêutica para melhora cognitiva e transtornos psicóticos
WO2006006071A1 (fr) * 2004-07-07 2006-01-19 Pfizer Products Inc. Resolution de compose azapolycyclique fusionne aryle
CN101128462A (zh) * 2005-02-24 2008-02-20 辉瑞产品有限公司 高纯度取代喹喔啉的制备
MX2008013606A (es) * 2006-04-24 2008-10-30 Pfizer Prod Inc Membranas asimetricas para dispositivos de administracion de farmacos.
JP2010527907A (ja) * 2006-11-09 2010-08-19 ファイザー・プロダクツ・インク ニコチン様中間体の多形体
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US8486979B2 (en) * 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
US20090062257A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched varenicline
WO2009034431A2 (fr) 2007-09-10 2009-03-19 Pfizer Inc. Formes posologiques à libération contrôlée de la varenicline
WO2009065872A2 (fr) * 2007-11-20 2009-05-28 Medichem, S.A. Procédés améliorés pour la synthèse de l-tartrate de varénicline
MX2010006202A (es) * 2007-12-07 2011-03-04 Abbott Gmbh & Co Kg Derivados de oxindol substituidos por amidometil y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
US8703774B2 (en) 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases
ES2397125T3 (es) * 2007-12-07 2013-03-04 Abbott Gmbh & Co. Kg Derivados de oxindol sustituidos con halógeno en la posición 5 y su uso para la producción de un medicamento para el tratamiento de enfermedades dependientes de la vasopresina
US8546401B2 (en) * 2007-12-07 2013-10-01 AbbVie Deutschland GmbH & Co. KG 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressin-dependent diseases
US8383657B2 (en) 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
EP2271344A4 (fr) * 2008-03-31 2011-04-27 Univ South Florida Méthodes de traitement d'une ataxie et d'un déséquilibre non-ataxique induits par une maladie
US8039620B2 (en) * 2008-05-22 2011-10-18 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline L-tartrate
US20090318695A1 (en) * 2008-06-19 2009-12-24 Vinod Kumar Kansal Processes for the preparation of varenicline and intermediates thereof
WO2010005643A1 (fr) * 2008-07-10 2010-01-14 Teva Pharmaceutical Industries Ltd. Procédés de purification du sel l-tartrate de varénicline et préparation de formes cristallines du sel l-tartrate de varénicline
US8314235B2 (en) * 2008-09-01 2012-11-20 Actavis Group Ptc Ehf Process for preparing varenicline, varenicline intermediates, pharmaceutically acceptable salts thereof
AU2010214101A1 (en) * 2009-02-11 2011-09-01 Sunovion Pharmaceuticals Inc. Histamine H3 inverse agonists and antagonists and methods of use thereof
WO2010138600A2 (fr) 2009-05-29 2010-12-02 Abbott Laboratories Compositions pharmaceutiques utilisées dans le traitement de la douleur
WO2010151524A1 (fr) * 2009-06-22 2010-12-29 Teva Pharmaceutical Industries Ltd Formes solides des sels de varénicline et leurs procédés de préparation
KR20180101268A (ko) 2017-03-03 2018-09-12 주식회사 씨티씨바이오 바레니클린 또는 이의 약학적으로 허용가능한 염의 포접 복합체를 포함하는 구강 투여용 제제
EP4084797A4 (fr) * 2020-01-03 2024-02-21 Blue Oak Pharmaceuticals, Inc. Composés et compositions pour le traitement de troubles du système nerveux central
CN115322105A (zh) * 2021-05-11 2022-11-11 江苏润安制药有限公司 一种合成艾拉莫德关键中间体的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471503A (en) 1967-05-05 1969-10-07 Mcneilab Inc 1,2,3,5,6,7-hexahydro-4-phenethyl-2,6-methano-4h-4- benzazonin-12-ols
SG102686A1 (en) * 1997-12-31 2004-03-26 Pfizer Prod Inc Aryl fused azapolycyclic compounds
EP0955301A3 (fr) 1998-04-27 2001-04-18 Pfizer Products Inc. Dérivés de 7-aza-bicyclo[2.2.1]-heptane, leur préparation et utilisation sur la base d'affinité pour les recepteurs de l'acetylcholine nicotinique neuronaux
WO1999055680A1 (fr) 1998-04-29 1999-11-04 Pfizer Products Inc. Composes azapolycycliques a fusion aryle
HUP0200332A3 (en) * 1999-01-29 2002-09-30 Abbott Lab Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands pharmaceutical compositions comprising thereof and their use
FR2788982B1 (fr) * 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
EP1372692A4 (fr) * 2001-03-19 2005-10-26 Sloan Kettering Inst Cancer Synthese asymetrique de (s,s,r)-(-)-actinonine, de ses analogues et ses utilisations
BRPI0412880A (pt) * 2003-07-21 2006-10-03 Pfizer Prod Inc compostos azapolicìclicos fundidos a arila
US8123947B2 (en) 2007-10-22 2012-02-28 Baxter International Inc. Priming and air removal systems and methods for dialysis

Also Published As

Publication number Publication date
DK1619192T3 (da) 2010-03-29
CR6726A (es) 2003-10-28
AP1860A (en) 2008-07-02
NO323608B1 (no) 2007-06-18
ATE328872T1 (de) 2006-06-15
AP2002002604A0 (en) 2002-09-30
IS6459A (is) 2002-07-05
DE60120366T2 (de) 2007-07-05
IL150639A (en) 2011-10-31
HK1050894A1 (en) 2003-07-11
SK12042002A3 (sk) 2004-02-03
BR0108610A (pt) 2002-11-19
EE200200475A (et) 2003-12-15
SI1259489T1 (sl) 2006-10-31
HRP20020700A2 (en) 2004-12-31
EP1619192A2 (fr) 2006-01-25
ATE453643T1 (de) 2010-01-15
US7144882B2 (en) 2006-12-05
UA74813C2 (en) 2006-02-15
RS51123B (sr) 2010-10-31
AU784081B2 (en) 2006-02-02
CY1105301T1 (el) 2010-03-03
BG65891B1 (bg) 2010-04-30
CZ20022778A3 (cs) 2003-09-17
EP1259489B1 (fr) 2006-06-07
NO20024042L (no) 2002-10-17
NZ519973A (en) 2004-04-30
PL365163A1 (en) 2004-12-27
AU2874801A (en) 2001-09-03
DK1259489T3 (da) 2006-10-09
KR20030005209A (ko) 2003-01-17
CA2401229C (fr) 2007-10-02
ES2263640T3 (es) 2006-12-16
US7205300B2 (en) 2007-04-17
ES2336800T3 (es) 2010-04-16
AU2005234671A1 (en) 2005-12-15
EA200200716A1 (ru) 2003-02-27
OA12181A (en) 2006-05-09
CN1406227A (zh) 2003-03-26
EA005316B1 (ru) 2004-12-30
YU59602A (sh) 2005-06-10
DZ3328A1 (fr) 2001-08-30
US6605610B1 (en) 2003-08-12
MXPA02008311A (es) 2002-12-09
CN1263745C (zh) 2006-07-12
DE60140965D1 (de) 2010-02-11
CZ303203B6 (cs) 2012-05-23
BG106908A (bg) 2003-04-30
GEP20053454B (en) 2005-02-25
DE60120366D1 (de) 2006-07-20
US20030130260A1 (en) 2003-07-10
PT1259489E (pt) 2006-08-31
ZA200206768B (en) 2003-09-23
NO20024042D0 (no) 2002-08-23
AU2005234671B2 (en) 2008-04-17
CU23148A3 (es) 2006-06-29
IL150639A0 (en) 2003-02-12
EP1619192B1 (fr) 2009-12-30
EP1619192A3 (fr) 2006-03-22
IS2293B (is) 2007-10-15
JP2003524002A (ja) 2003-08-12
EP1259489A1 (fr) 2002-11-27
WO2001062736A1 (fr) 2001-08-30
KR100537976B1 (ko) 2005-12-21
HUP0204580A3 (en) 2005-04-28
US20030130261A1 (en) 2003-07-10
CA2401229A1 (fr) 2001-08-30
HUP0204580A2 (hu) 2003-04-28
HU229482B1 (en) 2014-01-28

Similar Documents

Publication Publication Date Title
MA26875A1 (fr) Composes azapolycycliques a noyau aryle condensé
MA27596A1 (fr) Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
MA27438A1 (fr) Piperazines heterocycliques substituees pour le traitement de la schizophrenie
MA27568A1 (fr) Derives de pyrrolopyrimidine
TNSN98237A1 (fr) Composes azapolycycliques a noyau aryle condense, procede pour leur preparation et compositions pharmaceutiques les contenant
MA27439A1 (fr) Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase
MA31373B1 (fr) Composes amino-heterocycliques
MA26689A1 (fr) Derives de tetrahydroquinoleine substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA27138A1 (fr) Composes heteroaryliques condenses a substituant azabicyclique pour le traitement d'une maladie
TNSN04137A1 (fr) Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
MA27451A1 (fr) Derives de thiazole pour le traitement de troubles neurodegeneratifs
MA26957A1 (fr) Spiro-pyrimidine-2,4,6-triones inhibitrices de metalloproteinases.
MA31800B1 (fr) Dérivés de tétrahydroquinoléine pour traiter des troubles de stress post-traumatique
MA26864A1 (fr) Antagonistes du facteur de liberation de corticotrophine.
MA29685B1 (fr) Composes spiroheterocycliques et leurs utilisations en tant qu'agents therapeutiques
TNSN06200A1 (fr) Derives de quinoleine nouveaux
HUP0101281A2 (hu) Glicin transzport inhibitor hatású difenil-piperidin-butánamid-származékok, eljárás előállításukra, alkalmazásuk gyógyszerkészítmények előállítására és a vegyületeket tartalmazó gyógyszerkészítmények
TNSN97044A1 (fr) Derives de quinoxalinedone, procedes et intermediaires pour leur preparation, et compositions pharmaceutiques les contenant.
MA26701A1 (fr) PYRAZOLOPYRIMIDINONES NOUVELLES INHIBITRICES DE PDE-5 GMPc, PROCEDE POUR LEUR PREPARATION ET COMPOSTIONS PHARMACEUTIQUES LES CONTENANT.
MA26690A1 (fr) COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE PYRIDO [1,2-a ] PYRAZINE ET PROCEDE POUR LEUR PREPARATION
TNSN07366A1 (fr) Tetrahydro-pyridoazepine -8- ones et composes apparentes, pour le traitement de la schizophrenie
TNSN98151A1 (fr) Derives de 2 - (4 - aryl - ou heteroaryl - piperazine - 1 - ylmethyl) -1 h - indole.
MA27197A1 (fr) Sels de tolterodine
MA26953A1 (fr) Derives de pipérazine pontés.
FR2716883B1 (fr) Nouveaux dérivés tétrasubstitués de l'imidazole, leur préparation, nouveaux intermédiaires obtenus, leur application à titre de médicaments, compositions pharmaceutiques les renfermant.